Judith Martin
Pittsburgh, PANPI 1033183843
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,125 of the $1,197 with a category attached, or 94.0%. Every reported general payment came from a single manufacturer, Merck. Reporting peaked in 2021 at $1,125 and has fallen 97.0% since, to $34 in 2022.
Across 4 payments — averaging $299.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
Across 237 payments — averaging $3481.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$342K
- Merck$213K
- AstraZeneca$142K
- GSK$111K
- Pfizer$13K
- Astrazeneca UK Limited$6K
What the payments were for
- Consulting fees$1,12594%
- Food & beverage$726%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 4 | $1,197 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.